We currently represent several high quality biotech companies in multi-track licensing and M&A engagements, including:

  • A company with a novel proprietary first-in-class immunotherapy platform for solid and liquid tumors, with four clinical candidates, the most advanced in Ph II trials, available for licensing.
  • A company with novel monoclonal antibody targeting HGF, ready for Ph II, with excellent safety and indication of activity in gastric cancer, with dominant IP position, available for licensing.
Download our presentation
PDF

Get a digital copy of our PDF presentation

Download PDF